TBI is a major cause of death and disability in the United States; DRG Epidemiology estimates that there were 250,000 moderate to severe TBI events diagnosed in U.S. hospitals / emergency rooms in 2019. Although numerous generic drugs are available to manage acute-phase risks and chronic symptoms / deficits (e.g., pain, psychiatric problems, motor problems), no therapies are FDA approved to treat any aspect of TBI. As such, the opportunity for proven symptomatic or, more importantly, neuroprotective / restorative compounds for use in the acute and rehabilitation settings is entirely untapped. The TBI pipeline is small and evolving, but development challenges abound, and repeated failures in treating this complex disorder have stunted progress. A solid grasp of the addressable TBI market, the current state of management, and the future competitive landscape will lay the foundation for new players entering this space.
- How is TBI treated in the acute and rehabilitation settings today?
- What are the key areas of unmet need and opportunity in TBI?
- What are the key drivers and limiters of the therapy market?
- How will future players influence the various segments of the TBI market?
- What is the potential impact of new launches, and how might these therapies affect future opportunity in TBI? What do KOLs think?
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
- Traumatic Brain Injury - Executive Insights - Executive Insights (US)
- Executive Insights - 2020 - Traumatic Brain Injury
Author(s): Joyce Spadafora, ALM
Joyce is a business insights analyst in Decision Resources Group’s central nervous systems and ophthalmology division, where she provides expert insight into commercial aspects of drug development and market sizing across psychiatric and pain indications. She has worked extensively in DRG’s schizophrenia and chronic pain content.
Prior to joining DRG, Joyce spent several years in the biotech industry focused in research and development and in biotech consulting. Her project experience covered indications including psychiatry, pain, infectious diseases, respiratory, and ophthalmology. Beyond my therapeutic and industry knowledge, she holds a Masters in Extension Studies in Psychology from Harvard University and a B.S in Mechanical Engineering with Biology from the Massachusetts Institute of Technology.